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Abstract 
Introduction: Chronic obstructive pulmonary disease (COPD) is associated with an oxidant-
antioxidant imbalance. COPD patients have impaired cerebral vasoreactivity (CVR). Impaired CVR 
could be correlated with total antioxidant status (TAS) in plasma. 
Aim: To determine the role of systemic TAS in CVR of COPD patients. 
Material and Methods: In this cross-sectional observational study, we included 120 participants (the 
mean age of 67±7.9, 87 males), 90 COPD patients categorized according to the severity of airway 
obstruction in mild, moderate, severe/very severe and 30 age- and sex-matched controls. We 
analyzed baseline mean flow velocities (MFV) of the middle cerebral artery (MCA) and the basilar 
artery (BA), the mean breath-holding index (BHIm) of those arteries (BHImMCA and BHImBA) by 
transcranial Doppler ultrasound and TAS in plasma. The level of significance was set to α=0.05. 
Results: A significant negative correlation between TAS and BHImBA (Rho=−0.445, P=0.01) was found 
only in the mild COPD group. In COPD groups, baseline MFV BA is in a significant positive correlation 
with BHImMCA and BHImBA (Rho=0.336, P=0.001 and Rho=0.647, P<0.001). According to the severity 
of airway obstruction in COPD groups, a significant positive correlation between baseline MFV BA 
and BHImBA was found: in mild (Rho=0.731, P<0.001), moderate (Rho=0.574, P=0.001) and severe/very 
severe (Rho=0.398, P=0.03). 
Conclusion: Systemic TAS was not correlated with CVR in all COPD groups. However, perfusion in 
the BA of COPD groups was in a significant positive correlation with the anterior and posterior CVR. 
The analysis of perfusion in the basal cerebral arteries should be part of a future study of CVR in 
COPD patients.  
(Hlavati M, Tomić S, Buljan K, Butković-Soldo S. The Role of Total Antioxidant Status in Cerebral 
Vasoreactivity of Chronic Obstructive Pulmonary Disease Patients. SEEMEDJ 2020; 4(2); 48-61) 
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Introduction 
The coexistence of chronic obstructive 
pulmonary disease (COPD) and vascular disease 
is known, but the pathophysiology of this 
association has not been fully elucidated. The 
regulation of the cerebral blood flow (CBF) could 
be altered by some extrapulmonary 
consequences, such as arterial blood gas levels, 
acid-base imbalance, oxidative burden, 
endothelial dysfunction and autonomic 
disorders (1,2). The strongest regulator of the 
CBF is the arterial partial pressure of carbon 
dioxide (PaCO2). Large changes in the flow could 
result even from its small fluctuations. The 
change in the CBF for a given increase in arterial 
carbon dioxide (CO2) is greater than the change 
in the CBF observed for the same magnitude 
reduction in arterial CO2 (3). 
COPD patients have high oxidative stress 
associated with the severity of airway 
obstruction (4). Oxidative stress occurs when the 
resident antioxidants are insufficient or fail to 
upregulate sufficiently to neutralize an 
increased oxidant burden (5). In COPD, increased 
oxidative stress causes pulmonary inflammation. 
There is experimental and clinical evidence that 
pro-inflammatory mediators from the lungs 
overflow into the systemic circulation and cause 
the alteration of blood vessel structure. The 
vascular modelling and arterial stiffness lead to 
endothelial dysfunction. Those dysfunctional 
cells reduce the bioavailability of  the vasoactive 
substance they secrete, such as nitric oxide 
(NO), which otherwise causes relaxation of 
smooth muscle cells lining in arterioles (6). The 
sensitivity of cerebral blood vessels to changes 
in PaCO2 is termed cerebral vasoreactivity 
(CVR), where arterial hypercapnia induces 
vessel dilatation and causes an increase in 
cerebral perfusion (7). Damaged endothelial 
function is associated with impaired CO2 
reactivity, causing impairment of CVR. 
Therefore, CVR could be a surrogate of 
cerebrovascular endothelial function (8).  
COPD patients have impaired CVR in the anterior 
and posterior cerebral circulation and the 
impairment increases with the airway 
obstruction severity (9). A study that analyzed 
moderate smoking-related COPD 
postmenopausal women showed altered 
cerebrovascular responses in the anterior 
cerebral circulation to hypercapnia. They 
exhibited increased oxidative stress, suggesting 
that it may be significant in the dysfunction of 
CVR observed during hypercapnic challenge in 
COPD (10). Different methods defining total 
antioxidant status (TAS) of different biological 
samples have been developed and some of 
them can determine TAS in the plasma of COPD 
patients (11). The aim of this study was to 
determine the role of systemic TAS in CVR of 
COPD patients. 
Material and Methods  
Study subjects 
A cross-sectional observational study was 
conducted at the general hospital between 
March and August 2018. One hundred twenty 
participants were included in the study – 90 
COPD patients (mild, moderate and severe/very 
severe group, each consisting of 30 participants) 
and 30 healthy volunteers with a mean age 67 ± 
7.9, from which 87 males (Student’s T test, P = 
0.27). In terms of gender, there were no 
significant differences between the proportion 
of men and women in COPD patients and the 
control group (74.4 vs. 66.7 and 25.6 vs. 33.3% 
respectively; P = 0.41; Fisher's exact test). The 
baseline characteristics of COPD patients and 
controls were summarized in Table 1. The 
exclusion criteria were as follows: previous 
cerebrovascular disease, stenosis of internal 
carotid arteries (>50%), inadequate trans-
temporal acoustic window/s, atrial fibrillation, 
active malignity, exacerbation of COPD in 
previous two months, specific therapies 
(nonsteroidal anti-inflammatory and antioxidant 
therapy, vitamins A, C and/or E 
supplementation). COPD patients with arterial 
hypertension, hyperlipidemia, ischemic heart 
disease and diabetes mellitus that represent 
vascular disease risk factors were included if 
they were under good therapy control. 
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Age (years) 64 (4) 67 (9) 1.8‡ -5.1 do 1.5 0.27 
FEV1/FVC ratio [Median 
(interquartile range)] 
0.80  
(0.75 – 0.83) 
0.61 
(0.46 – 0.68) 
0.20‡ 0.15 do 0.25 <0.001† 
FEV1 (%) 106 (12.7) 65 (25.5) 40.7 33.6 do 47.7 <0.001 
BMI (kg/m2) 27.2 (3.2) 28.7 (6.7) 1.5 -4.03 do 0.97 0.23 
Body temperature (°C) 35.3 (5.7) 35.9 (3.3) 0.64 -2.3 do 1.04 0.45 
Systolic blood pressure 
(mmHg) 
130 (13) 135 (16) 5,2 -11.6 do 1.2 0.13 
Diastolic blood pressure 
(mmHg) 
80 (5) 81 (6) 0,8 -3.5 do 1.8 0.53 





(0.97 – 3.15) 
2.6 
(1.4 – 6.2) 
0.6‡ -0.1 do 1.6 0.08† 
Pack-years [Median 
(interquartile range)] 
41 (17.3 - 48) 43 (33 - 55) 9‡  -6.8 do 30 0.27† 
*Student T test; †Mann-Whitney U test; ‡Hodges-Lehmann median difference    
FEV1/FVC – forced expiratory volume in one second / forced vital capacity; FEV1 −  forced expiratory volume in one second; BMI – 
body mass index; CRP – C-reactive protein; pack-years = number of cigarettes per day x number of smoking years / 20 
 
Study design 
The participants were divided into four groups. 
The first three groups were COPD patients, 
divided according to spirometry findings and the 
Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) classification of airflow 
obstruction severity based on forced expiratory 
volume in one second (FEV1) as mild; moderate; 
and severe to very severe (12). According to 
GOLD, COPD was defined by post-
bronchodilator FEV1 to forced vital capacity 
(FVC) ratio (FEV1/FVC) of <0.70, confirming a 
persistent airflow obstruction (13). The fourth 
group were controls − healthy volunteers 
(FEV1/FVC >70% and FEV1 >80% of the 
predicted value).  
Anthropometric measurements, comprising 
height and weight, were determined. Body mass 
index (BMI) was calculated and expressed as 
weight (kg) / height (m2). Pack-years were 
calculated as the number of cigarettes per day x 
the number of years smoked /20 (14). The 
participants were asked to abstain from caffeine, 
alcohol and intense physical activity at least 12 
hours prior to participation in the study. For all 
participants, the exclusion of significant internal 
carotid stenosis was performed by the method 
of color and power Doppler flow imaging with a 
linear probe (VF 10-5 Linear Ultrasound 
Transducer, Siemens Acuson X300, Germany). 
For all participants, a specialized technician 
performed spirometry (Spiroscoutᴿ Ganshorn, 
Germany) according to the American Thoracic 
Society/European Respiratory Society 
standardization (15). Baseline cerebral perfusion 
and CVR were determined by transcranial 
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Doppler (TCD) ultrasound (DigiLite™, Rimed, 
Industrial Park Raanana, Israel).  
The study was approved by the Ethics 
Committee of General Hospital Našice (No. 01-
497/3-2017) and by the Ethics Committee of the 
Faculty of Medicine Osijek, Josip Juraj 
Strossmayer University of Osijek, Croatia (No. 
2158-61-07-17-209). All data were anonymized 
and the study was conducted in accordance 
with the amended Declaration of Helsinki. 
Informed consent was obtained from all 
individual participants included in the study. All 
participants signed an informed consent form 
before entering the study. 
Biochemical analysis 
Venous blood was taken for a biochemical 
analysis. We analyzed the complete blood count 
(Sysmax XN-1000 SA-01, Sysmax Europe 
GmbH), C-reactive protein (CRP) and TAS 
(Beckman Coulter DXC 700 AU analyzer, USA). 
The plasma antioxidant status was measured 
using a commercially available TAS kit (reagents 
Randox Laboratories Ltd, United Kingdom). The 
serum separated from blood was frozen at -20 
ºC. The samples were collected over a period of 
14 days and analyzed in one day by using a 
colorimetric assay. The procedure was repeated 
until the target number of participants was 
reached. The reference range was set at 1.30 – 
1.77 and the results were expressed as mmol/L 
(16). Other blood samples were analyzed 
immediately after being taken. 
TCD monitoring 
TCD monitoring of the middle cerebral arteries 
(MCAs) that represent the anterior cerebral 
circulation was performed by previously 
described protocol (9,17,18). The breath-holding 
test was used as a hypercapnic stimulus. Using 
an original headband device (Rimed, Industrial 
Park Raanana, Israel), we secured both 2-MHz 
Doppler probes over the trans-temporal 
windows. An optimal insonation position during 
monitoring was maintained and escaped 
movement artifacts. Baseline mean flow velocity 
(MFVbaseline) was defined as a continuous 
mean velocity over 30 seconds during the 
resting period in supine position and normal 
breathing of room air. Maximum MFV (MFVmax) 
was defined as the last 3 seconds of breath-
holding after normal inspiration. The minimum 
breath-holding time was set at 15 seconds and 
the maximum at 30 seconds. The test was 
repeated two times, with a resting period of 2 
minutes. Breath-holding index (BHI) was 
calculated as the difference in the increase of 
MFV (cm/s) occurring during breath-holding 
divided by the time (seconds) for which the 
participant held breath ([MFVmax -MFVbaseline] 
/ breath-holding time). We were calculating BHI 
of each test on the right and left side and then 
the mean BHI (BHIm) for each participant. The 
testing of the basilar artery (BA) that represents 
the posterior cerebral circulation was performed 
in a seated position, using the same handheld 
suboccipital insonation probe. Testing was 
repeated twice to calculate BHIm of the BA. 
Among the Croatian population, normal BHI 
values range from 1.03 to 1.65 (17). 
Statistical analysis 
The sample size was calculated to be 120, effect 
size 0.35, level of significance 0.05 and power 0.9 
(G*power software, version 3.1.9.2, by Franz Faul, 
University Kiel, Germany). Local ethics 
committees approved the study.  
The category data are represented by absolute 
and relative frequencies. Differences between 
categorical variables were tested by the χ2 test, 
and, if necessary, by the Fisher exact test. The 
normality of the distribution of numeric variables 
was tested by the Shapiro-Wilk test.  
Numerical data are described by the arithmetic 
mean and standard deviation in case of a normal 
distribution, and by the median and the limits of 
the interquartile range in cases where the 
distribution is not normal. The means of the 
numerical variables of interest were evaluated 
using a 95% confidence range. The Student's t-
test and Mann-Whitney's U test (with Hodges-
Lehmann median difference) were used to test 
the differences in the numerical variables 
between two independent groups of subjects, 
depending on the normality of the distribution. 
The Kruskal-Wallis (post-hoc Conover) test was 
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used to test for differences in the numerical 
variables between three or more independent 
groups. The correlation of the numerical 
variables was evaluated by the Spearman 
correlation coefficient ρ (rho). The differences in 
the numerical variables before and after testing 
were tested with the Wilcoxon test (19). All P 
values were two-sided. The level of significance 
was set at Alpha=0.05. MedCalc Statistical 
Software version 18.11.3 (MedCalc Software 
bvba, Ostend, Belgium; 
https://www.medcalc.org; 2019) and SPSS (IBM 
Corp. Released 2015. IBM SPSS Statistics for 
Windows, Version 23.0. Armonk, NY: IBM Corp.) 
were used for all analyses. 
Results 
The baseline characteristics of COPD patients 
according to the severity of airflow obstruction 
were summarized in Table 2. 
Table 2. Baseline characteristics, lung functions, laboratory values and pack-years in COPD groups 
 
Median (interquartile range)  
P* 
               Mild Moderate 




                    66 
          (59 – 70) 
                  68 
(62 – 72) 
                   71 
(65 – 78) 
                68  





                  0.68  
       (0.67 – 0.69) 
0.645  
(0.57 – 0.68) 
0.41 
 (0.34 – 0.48) 
              0.68 
 (0.67 – 0.69) 
<0.001 
† FEV1 (%) 
93.5  
(87.8 – 103.5) 
64 
 (56 – 69.3) 
37 
 (31 – 42.8) 
64 




 (26.9 – 31.7) 
31.7 
(25.9 - 35) 
24  
(19.9 – 29.2) 
28.6 





 (36 – 36.5) 
36.1 
(36 – 36.3) 
36.3  
(36 – 36.5) 
36.2 





 (130 - 150) 
132.5 
 (120 - 146) 
130 
 (120 – 142.5) 
132.5 





 (80 - 90) 
80 
 (80 - 85) 
78 
 (70 - 80) 
80 




 (130.5 – 150.3) 
147.5  
(135 - 154) 
144  
(131.75 - 158) 
144 







 (1.3 – 4.6) 
2.5 
 (1.6 – 6.2) 
2.95 
 (1.3 – 7.73) 
2.6  




 (31.8 – 52.5) 
43 
 (27.6 - 51) 
49 
 (41.5 – 73.88) 
43 
(33.5 – 54.4) 
0.15 
*Kruskal-Wallis test (Post-hoc Conover); †on level P < 0.05 significant differences between mild vs. moderate, mild vs. severe/very 
severe, moderate vs. severe/very severe; ‡on level P < 0.05 significant differences between mild vs. severe/very severe, moderate 
vs. severe/very severe 
FEV1/FVC – forced expiratory volume in one second / forced vital capacity; FEV1 − forced expiratory volume in one second; BMI – 
body mass index; CRP – C-reactive protein; pack-years = number of cigarettes per day x number of smoking years / 20 
Arterial hypertension was significantly less 
observed in the severe/very severe COPD 
group (χ2 test, P = 0.003) and there were no 
differences in the presence of hyperlipidemia, 
ischemic heart disease and diabetes mellitus 
among the COPD groups (data not presented).   
Significant differences were found in baseline 
MFV of MCA. In COPD groups, higher velocity 
was on the left, and in controls on the right MCA. 
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Baseline MFV of MCA and BA and also 
BHImMCA and BHImBA were significantly lower 
in COPD patients than in controls. TAS was 
significantly higher in COPD than controls (Table 
3). 
Table 3. Baseline MFV, cerebral vasoreactivity and TAS in COPD patients and controls 
 
Median (interquartile range) 
P* 
Controls P* COPD P* 
MFV MCA right (cm/s) 37  
(29.8 – 44.3) 
<0.001 
30  
(23 - 35) 
<0.001 
0.004 
MFV MCA left (cm/s) 34.5  
(30 – 40.5) 
31 
 (23 – 39.25) 
0.01 
MFV BA (cm/s) 29,5 
 (26 – 30.3) 
- 
24.5 
 (17 – 30.3) 
- 0.003 
BHImMCA 1.24 
 (1.16 – 1.39) 
- 
0.8  
(0.7 – 0.9) 
- <0.001 
BHImBA 1.07 
 (1.02 – 1.15) 
- 
0.7 




(1.5 – 1.7) 
- 
1.7 
 (1.5 – 1.8) 
-     0.03 
*Mann-Whitney U test; †Wilcoxon test 
MFV – mean flow velocity; TAS – total antioxidant status; MCA – middle cerebral artery; BA – basilar artery; BHIm – breath-holding 
index mean 
 
In COPD groups, based on greater severity of the 
disease, there were significant reductions in 
baseline MFV of MCA and BA and we found 
significant impairment of BHImMCA and 
BHImBA (Table 4). 
 
Table 4. Baseline MFV, cerebral vasoreactivity and TAS in COPD groups 
 
Median (interquartile range)  
P* 




MFV MCA right 
(cm/s) 
            32  
(29.8 - 39) 
0.78 
            30.5  
(18 – 39.25) 
0.53 
              26 
 (19 – 32.5) 
0.91 
0.02† 
MFV MCA left 
(cm/s) 
          32.5 
(25.8 - 41) 
            31.5 
 (23 – 37.75) 
            24.5  
(17.8 – 33.3) 
0.04† 
MFV BA (cm/s)             28 
 (20.8 – 32.3) 
- 
             22.5 
   (17 – 30.3) 
- 
                19 
 (14.5 – 29.3) 
- 0.04† 
BHImACM 
          0.94 
 (0.89 – 1.06) 
- 
              0.8 
 (0.7 – 0.9) 
- 
               0.7 
     (0.6 – 0.7) 
- <0.001‡ 
BHImAB  
            0.83 
 (0.72 – 1.03) 
- 
             0.7 
  (0.6 – 0.9) 
- 
                0.6 
      (0.4 – 0.7) 
- <0.001‡ 
TAS (mmol/L) 
             1.6 
 (1.52 – 1.78) 
- 
             1.7 
 (1.6 – 1.8) 
- 
                1.7 
      (1.6 – 1.8) 
- 0.52 
*Kruskal-Wallis test (post-hoc Conover); †on level P < 0.05 significant differences between mild vs. severe/very severe; ‡on level P 
< 0.05 significant differences between mild vs. moderate, mild vs. severe/very severe, moderate vs. severe/very severe; §Wilcoxon 
test 
MFV – mean flow velocity; TAS – total antioxidant status; MCA – middle cerebral artery; BA – basilar artery; BHIm – breath-holding 
index mean 
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Using the Spearman's rank correlation 
coefficient, a significant negative correlation was 
found between age and BHImBA in controls. In 
COPD groups, we found a significant negative 
correlation between age and BHImMCA and 
BHImBA. In the COPD group, baseline MFV of BA 
is in a significant positive correlation with 
BHImMCA and BHImBA (Table 5). 
Table 5. Correlation between age and baseline MFV BA with BHIm MCA and BHIm BA in COPD 
patients and controls 
 Spearman's rank correlation coefficient Rho (P value) 
Age (year)  MFV BA (cm/s) 
Controls    
BHImMCA   -0.089 (0.64)      0.051 (0.79) 
BHImBA   -0.376 (0.04)     0.124 (0.51) 
COPD    
            BHImMCA -0.375 (< 0.001)    0.336 (0.001) 
            BHImBA -0.376 (< 0.001)  0.647 (<0.001) 
MFV – mean flow velocity; BHIm – breath-holding index mean; MCA – middle cerebral artery; BA – basilar artery 
 
TAS and BHImBA significantly negatively 
correlated only in COPD groups, but not in the 
control group (Figure 1). 
 
Figure 1. The correlation between total antioxidant status (TAS) and mean breath-holding index of 
the basilar artery (BHImBA) in COPD patients and controls 
 
Using the Spearman's rank correlation coefficient Rho, we found a significant negative correlation between TAS and BHImBA (Rho= 
−0.327, P=0.002) in COPD patients and no significant correlation in controls. 
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Figure 2. The correlation between total antioxidant status (TAS) and mean breath-holding index of 
the basilar artery (BHImBA) according to COPD severity 
 
Using the Spearman's rank correlation coefficient Rho, we found a significant negative correlation between TAS and BHIm BA (Rho= 
−0.445, P=0.01) in the mild COPD groups and no significant correlations in other COPD groups. 
 
There were no significant correlations between 
TAS and BHImMCA in COPD groups, nor 
between TAS and BHImMCA in the control 
group (data not presented). Using the 
Spearman's rank correlation coefficient Rho, 
based on the severity of COPD and age, a 
significant negative correlation was found 
between age and BHImBA (Rho= −0.398, P=0.03) 
in the moderate group. In the severe/very 
severe COPD group, a significant negative 
correlation was found between age and 
BHImMCA (Rho= −0.451, P= 0.01), but there were 
no significant correlations in other COPD groups 
(data not presented).  
In terms of the severity of airway obstruction, we 
found a significant negative correlation between 
TAS and BHImBA only in the mild COPD (Figure 
2). There was no significant correlation between 
TAS and BHImMCA in any COPD group (data not 
presented).  In all COPD groups, a significant 
positive correlation waws found between 
baseline MFV BA and BHImBA (Figure 3), but 
there was no correlation between MFV BA and 
BHImMCA (data not presented). 
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Figure 3. The correlation between baseline mean flow velocity of the basilar artery (MFV of BA) and 
mean breath-holding index of the basilar artery (BHIm BA) based on COPD severity   
 
Using the Spearman's rank correlation coefficient Rho, we found a significant positive correlation between baseline MFV BA and 




The aim of the study was to analyze the 
relationship between CVR and TAS in the 
plasma of COPD patients and controls. In COPD 
patients, TAS was in a significant negative 
correlation with CVR in the posterior cerebral 
circulation, but in terms of the severity of airflow 
obstruction, we found a negative correlation 
between CVR and TAS in the posterior cerebral 
circulation only in the mild COPD group. There 
was no significant correlation between CVR and 
TAS in the anterior cerebral circulation. The 
results from this study do not allow conclusions 
that impaired CVR is associated with systemic 
changes in the antioxidative status of COPD 
patients. 
A significantly higher TAS values were found in 
COPD patients than in controls, which contrasts 
the previously published data. The reason for 
that could be multifactorial, but determining the 
mechanisms for was in the scope of our recently 
published manuscript, where we demonstrated 
that TAS is a predictor of COPD (20). 
In terms of gender, there were more men 
participating in the study than women, but they 
were equally represented in the COPD groups 
and in the control group. All women in the study 
have reached menopause. In that period, 
oxidative stress was reported to increase 
because of the decreasing levels of estrogen, 
which has beneficial vasoactive and 
antioxidative effects (21). A study of 
postmenopausal women with moderate COPD 
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related to smoking analyzed oxidative stress and 
CVR in the anterior cerebral circulation. The 
study showed an impaired cerebrovascular 
response to hypercapnia, significantly higher 
levels of oxidative stress, a higher level of 
glutation peroxidase that represents antioxidant 
enzyme activity and a higher ratio between 
oxidative stress and antioxidant activity than in 
controls. There was no significant correlation 
between the markers of oxidative 
stress/antioxidants and CVR measured by TCD. 
The only correlation was found between higher 
catalase activity, which represents antioxidant 
enzyme activity associated with higher 
ventilatory response sensitivity. In the context of 
higher oxidative stress caused by the decline of 
estrogen levels in menopause, it was concluded 
that that could be a possible explanation of the 
observed differences in cerebrovascular 
sensitivity to hypercapnia between COPD 
women and controls (10).   
Hypoxemia is part of clinical features of COPD 
patients. A recent study analyzed how lifetime 
exposure to hypoxia (3,600 m above sea-level, 
La Paz, Bolivia) affects oxidative stress, CVR and 
cognitive function. Chronic mountain sickness is 
a maladaptation syndrome experienced at high 
altitudes, characterized by severe hypoxemia. 
The syndrome is related to a higher risk of 
stroke, migraine, increased morbidity and 
mortality. It has been confirmed that individuals 
with such syndrome have exaggerated oxidative 
stress and a corresponding decrease in vascular 
NO bioavailability. Oxidative stress was 
associated with an impaired cerebrovascular 
function. The authors of this study concluded 
that oxidative stress induced by hypoxemia is 
associated with blunted cerebral perfusion, 
impaired CVR to hypercapnia, accelerated 
cognitive decline and depression (18).   
In our study, COPD patients had significantly 
impaired CVR. Impaired CVR, that is impaired 
CO2 vasoreactivity as a surrogate of endothelial 
dysfunction, results in a decline of NO (8). A 
recent study on an animal model showed that an 
increase in the bioavailability of NO through 
prostaglandin pathways causes vasodilatation; 
therefore, it increases oxygenation and 
produces higher TAS. That way, the antioxidant 
– TAS eliminates free radicals from biological 
systems (22). This conclusion is based on a 
previous study suggesting that as the TAS value 
increases, free radicals decrease, which protects 
macromolecules from damage (23). A recent 
study analyzed age- and apolipoprotein E 
(APOE) gene-specific hemodynamic changes 
using the blood-oxygen-level-dependent 
(BOLD) functional magnetic resonance imaging 
(MRI) method. The breath-holding method was 
used for the examination of CVR and visual 
stimulation tasks to evoke functional hyperemia. 
After a three-day intake of nitrate as a NO 
source, there was no effect on CVR or functional 
hyperemia, but CVR significantly decreased with 
age and was dependent on the genotype of 
participants. That way, the response of vascular 
functions on breath-holding could be 
dependent on the APOE-genotype and 
independent of NO (24).  Such an analysis far 
exceeds our technical capabilities, but it would 
certainly be useful to include a genetic analysis 
in the endothelial dysfunction analysis of COPD 
patients, in order to successfully manage 
therapeutic decisions, evaluate the response to 
target interventions and provide prognostic 
information.  
In our study, there were differences between the 
baseline right and left anterior cerebral 
perfusion in COPD patients and controls. 
Determining the mechanism(s) involved in those 
differences was not the goal of this study. Our 
opinion is that the differences observed were 
not significant for the ultimate results of the 
study.  
In COPD, the baseline anterior and posterior 
cerebral perfusion was significantly lower than in 
controls. Based on greater severity of COPD, a 
significant decline of perfusion was recorded in 
the anterior and posterior cerebral circulation. 
The baseline posterior cerebral perfusion was in 
a significant positive correlation with CVR of the 
anterior and posterior cerebral circulation in 
COPD, which was not found in controls. In terms 
of the severity of airway obstruction, all COPD 
groups had a significant positive correlation 
between the baseline posterior cerebral 
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perfusion and CVR in the posterior cerebral 
circulation. Decreased cerebral perfusion means 
reduced cerebral blood flow velocity. TCD 
perfusion analysis assumes that there is no 
change in the width of the artery lumen and that 
the blood flow is laminar. Despite that 
interpretation constraint of TCD, in the study, in 
cases when lower cerebral perfusion was 
recorded, that decrease correlated with an 
impaired ability of the cerebral arteries to 
respond to vasodilator stimuli, such as 
hypercapnia (18,25,26).   
In our study, a significant negative correlation 
was found between age and CVR in the posterior 
cerebral circulation only in the moderate COPD 
group and between age and CVR in the anterior 
cerebral circulation in the severe/very severe 
COPD group. Therefore, the results do not allow 
a final conclusion on the correlation between the 
age of COPD patients and CVR in our sample. In 
the study that used functional TCD and 
hypercapnic stimuli as a marker of CVR, the 
cerebral perfusion changes were determined as 
a response to the language and arithmetic task 
in healthy young, healthy old and old subjects 
with the risk factors for atherosclerosis. Arterial 
hypertension was the most frequent risk factor 
and the breath-holding method was used as a 
hypercapnic stimulus. The cerebral perfusion 
changes were significantly lower during the 
cognitive task and hypercapnia in the group of 
old subjects with vascular risk factors compared 
to the healthy young and old subjects. These 
results showed that the presence of cardio- and 
cerebrovascular risk factors significantly 
reduces the ability of cerebral vessels to react to 
vasoactive stimuli. Aging alone, without such risk 
factors, could not be responsible for 
hemodynamic changes caused by neuronal 
activation (27). In the study that used the pulsed 
arterial spin labelling perfusion MRI and BOLD 
methods, the regional cerebral blood flow and 
CVR were assessed in young and elderly 
participants. Age-related decreases in the 
baseline CBF and CVR were observed in the 
cerebral cortex, which may be related to the 
vulnerability to neurological disorders in aging 
(28). Detection of early dysfunction of the 
cerebral vascular system in older people with 
the risk of developing cognitive impairment 
ensure the possibility of vascular-specific 
procedures which help maintain cognitive 
function through a lifetime (29). The TCD 
ultrasound technique does not allow clear 
spatial resolution of CVR.  
The main limitation of the study was that TAS 
was the only biomarker that we performed 
because of technical and financial reasons. In 
comparison with clinical characteristics and 
individual biomarker, the combination of COPD 
markers increases the prognostic value for 
proper outcome monitoring (30,31). We did not 
analyze any of the oxidants, so the increased 
oxidative burden in our population is not clearly 
proven. On the other side, the choice of 
peripheral blood among other biological 
samples is more appropriate because of the 
non-invasiveness of blood sampling and its 
property of easily allowing repeated 
measurements (11).  
The main limitations of TCD, and therefore of our 
study, are its dependency on the operator, the 
presence of adequate insonation windows and 
the possibility of recording inaccurate mean flow 
velocities due to wrong insonation angles (32). 
The strength of TCD is that the estimation of 
cerebral blood flow velocity, that is cerebral 
perfusion and CVR by that method, using CO2 as 
a hypercapnic stimulus, has acceptable levels of 
reproducibility. It is an appropriate method for 
determining the effect of hypercapnia on 
cerebral haemodynamics (33).  
The correlations between CVR and systemic 
levels of the antioxidant marker of TAS in the 
plasma have not been demonstrated in all COPD 
groups. However, based on the decrease in 
perfusion in the anterior and posterior cerebral 
circulation detected in COPD patients compared 
to controls, there is a possible correlation 
between CVR and the initial perfusion in the 
basal cerebral arteries.  
According to previous studies, there are 
correlations between impaired CVR and the risk 
of stroke, progressive global vascular damage, 
an increased risk of mortality, especially 
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cardiovascular mortality, cognitive decline and 
dementia (34–38). Early detection of COPD 
patients at risk of these comorbidities presents 
an opportunity for early therapeutic 
interventions aimed at reducing such risks. 
Conclusion 
In our study, a negative correlation between CVR 
and the plasma level of TAS was found only in 
the posterior cerebral circulation in the mild 
COPD group. The results do not allow the 
conclusion that impaired CVR is associated with 
systemic changes in the antioxidative status of 
COPD patients. However, we found that 
decreased perfusion in the basilar artery of 
COPD patients was in a significant positive 
correlation with CVR of the anterior and posterior 
cerebral circulation, which was not observed in 
controls. The analysis of perfusion in the basal 
cerebral arteries should be part of a future study 
of CVR in COPD patients. 
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